Document Detail

Neuroimaging over the course of Parkinson's disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease.
MedLine Citation:
PMID:  23026362     Owner:  NLM     Status:  In-Data-Review    
Brain imaging of striatal dopamine terminal degeneration serves an important role in the clinical management of Parkinson's disease (PD). Imaging biomarkers for interrogating dopaminergic systems are used for clarifying diagnosis when only subtle motor symptoms are present. However, motor dysfunction is not the earliest symptom of PD. There is increasing interest in identifying premotor PD patients, particularly because potential disease-modifying therapies are developed and the clinical imperative becomes early and accurate diagnosis. On the other end of the spectrum of the disease course, during later stages of PD, significant clinical challenges like levo-dopa-induced dyskinesias and medication on-off phenomenon become more prevalent. In this instance, better understanding of altered PD motor pathways suggests the potential utility of novel treatments targeting neuronal systems that are impacted by degenerating dopamine neurons and chronic dopamine replacement treatment. Molecular neuroimaging serves unique roles in both very early PD and later-stage disease, in the former, potentially pushing back the time of diagnosis, and in the latter, elucidating pathology relevant to new drug development.
John Seibyl; David Russell; Danna Jennings; Kenneth Marek
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Seminars in nuclear medicine     Volume:  42     ISSN:  1558-4623     ISO Abbreviation:  Semin Nucl Med     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1264464     Medline TA:  Semin Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  406-14     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Institute for Neurodegenerative Disorders, New Haven, CT; Molecular Neuroimaging, LLC, New Haven, CT; Yale University School of Medicine, New Haven, CT. Electronic address:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nuclear medicine in cerebrovascular disease.
Next Document:  Neuronuclear imaging in the evaluation of dementia and mild decline in cognition.